Physician profile
Tejas Patel
NPI 1467421032
$8,194.94
in general payments reported to CMS, 2019-2025
47 companies · $1,288 in 2025
The $1,288 reported for 2025 was more than what 83% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.73 · 2020: $496 · 2021: $1,616 · 2022: $2,215 · 2023: $1,407 · 2024: $1,154 · 2025: $1,288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,436 · Education: $414.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,435.84 |
| Education | $413.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $1,707.41 | 2020-2025 | Rayaldee |
| Novartis Pharmaceuticals Corporation | $773.46 | 2019-2025 | |
| Vifor Pharma, INC. | $659.91 | 2020-2025 | Veltassa |
| Astrazeneca Pharmaceuticals LP | $634.37 | 2020-2024 | Farxiga, Lokelma |
| Amgen INC. | $500.44 | 2020-2025 | Repatha, Aranesp, Tavneos |
| Novo Nordisk INC | $487.84 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Travere Therapeutics, INC. | $351.09 | 2021-2025 | |
| Horizon Therapeutics Plc | $328.52 | 2021-2023 | Krystexxa |
| Abbvie INC. | $320.83 | 2021-2025 | |
| Abbott Laboratories | $242.63 | 2022-2025 | Freestyle Libre 3, Mitraclip |
| Otsuka America Pharmaceutical, INC. | $217.75 | 2020-2022 | |
| Mallinckrodt Hospital Products INC. | $204.81 | 2021-2025 | Acthar |
| Corcept Therapeutics | $158.89 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.52 | 2025 | Jardiance |
| Lilly USA, LLC | $148.99 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recor Medical INC | $138.92 | 2025 | Paradise Ultrasound Renal Denervation System |
| Allergan, INC. | $117.09 | 2022 | |
| Pfizer INC. | $103.77 | 2021-2024 | |
| Ardelyx, INC. | $91.98 | 2023-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $86.45 | 2020-2022 | |
| Alexion Pharmaceuticals, INC. | $68.29 | 2022-2023 | Ultomiris |
| Scpharmaceuticals INC. | $66.54 | 2025 | |
| Genzyme Corporation | $55.52 | 2022-2023 | |
| Mannkind Corporation | $52.14 | 2020-2021 | |
| Depuy Synthes Sales INC. | $43.07 | 2021 | |
| Intuity Medical INC | $37.84 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Dexcom, INC. | $35.48 | 2024 | Dexcom G6 Transmitter |
| Renalytix Ai, INC. | $32.40 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Esperion Therapeutics, INC. | $31.33 | 2024-2025 | Nexletol |
| Amneal Pharmaceuticals LLC | $25.00 | 2025 | Unithroid |
| Beta Bionics, INC. | $24.73 | 2024 | Ilet Bionic Pancreas |
| Fresenius USA Marketing, INC. | $24.45 | 2024 | Velphoro |
| Madrigal Pharmaceuticals | $24.24 | 2025 | Rezdiffra |
| Conmed Corporation | $23.65 | 2025 | Conmed Biliary |
| Fresenius USA Manufacturing, INC. | $23.13 | 2025 | |
| Ani Pharmaceuticals, INC. | $22.97 | 2022 | |
| Sumitomo Pharma America, INC. | $22.06 | 2024 | Gemtesa |
| Rhythm Pharmaceuticals, INC. | $19.94 | 2025 | Imcivree |
| Ibsa Pharma INC. | $16.80 | 2021 | |
| Philips North America LLC | $16.64 | 2024 | (Ck4) Mcot |
| Dynavax Technologies Corporation | $15.96 | 2025 | Heplisav-B |
| Glaxosmithkline, LLC. | $15.90 | 2025 | Shingrix, Arexvy |
| Eisai INC. | $14.75 | 2024 | |
| Calliditas Therapeutics US INC. | $13.60 | 2023 | Tarpeyo |
| Janssen Biotech, INC. | $12.92 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $11.92 | 2021 | |
| Cequr Corporation | $10.00 | 2023 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tejas Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.